Intranasal ketamine (Esketamine)

DRUG2 trials

Sponsors

Zylorion Health

Conditions

Treatment Resistant Major Depressive Disorder

Phase 2

Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression

TerminatedNCT05323019

Zylorion HealthTreatment Resistant Major Depressive Disorder

Start: 2022-10-13End: 2023-02-01Updated: 2023-03-24

Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study

WithdrawnNCT05438758

Zylorion HealthTreatment Resistant Major Depressive Disorder

Start: 2023-01-15End: 2024-03-01Updated: 2022-11-15